The Japanese Pharmaceutical Market Ranks Second in the World, Next Only to That of the US, With a Share of 11% in 2004
Posted on: Tuesday, 21 November 2006, 03:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c45571) has announced the addition of "Japanese Pharmaceutical Industry: An Analysis" to their offering.
The Japanese pharmaceutical market ranks second in the world, next only to that of the US, with a share of 11% in 2004.
The market comprises pharmaceutical manufacturers and marketers, contract manufacturers and pharmaceutical service providers. Prescription drugs dominate the market, while generic drugs usage is rising.
Recent changes in government policies are encouraging domestic pharmaceutical companies to explore cost-cutting options, such as outsourcing and contract manufacturing, to beat competition from foreign players.
Foreign investment in the pharmaceutical sector is on the rise, buoyed by favourable policies that, among other things, encourage companies to buy over local partners through stock swaps.
However, the drug price controls on the industry remain one of the major stumbling blocks to growth in the pharmaceutical sector.
This report analyzes the pharmaceutical sector in Japan and closely examines the emerging trends. It contains the profiles of the major companies - Takeda Pharmaceutical, Daiichi Sankyo, Astellas and Pfizer- and their business strategies. Additionally, an outlook for the sector has been provided in the report.
The market growth is being driven by an increase in the proportion of the elderly population (those above 65 years).
In an effort to cut down healthcare expenditure, the government has been encouraging consumers to shift from their traditional preference for branded products to generic drugs.
Some of the key findings include:
The research and development (R&D) capabilities of the country are less developed. Consequently, the drug development process is very slow compared to other large markets
The market for contract manufacturing activities will double by 2009
Topics Covered:
Market Dynamics
Industry Growth and Events
PEST Analysis
Michael Porters Five Forces Analysis
Competitive Landscape
Industry Outlook
Companies Mentioned:
Takeda Pharmaceutical
Sankyo
Astellas
Pfizer
For more information visit http://www.researchandmarkets.com/reports/c45571
Source: Business Wire
Related Articles
- Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
- Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines
- The French Pharmaceutical Market Has Been Experiencing Solid Growth In Recent Years
- Companies and Markets: China Healthcare Sector Analysis Market Report Available Now
- Must Know Business and Marketing Strategy for China's Pharmaceutical Market
- 'Access to Hospital Pharmaceutical Markets in the United Kingdom' - the Hospital Drug Bill Has Been Rising at More Than Twice the Rate of GP Prescribing Costs
- Global Pharmaceutical Market to Double in Value to $1.3 Trillion By 2020, Estimates PricewaterhouseCoopers, But Industry Must Change to Capitalize On Opportunities
- Antisense Oligonucleotides Have Been in Clinical Trials for Cancer for Some Time Now - Drug Delivery in Cancer - Technologies, Markets and Companies Report 2007
- Pharmaceutical and Biotechnology Companies Are Increasingly Shifting Their Drug Development for Infectious Diseases From Antibacterial to Antiviral Discovery and Development
- See the TOP 100 Drug IV-Rating for Products Promoted on the Russian Pharmaceutical Market
 |
 |
User Comments (0)
RSS Feeds